Chongqing Zhifei Bio Products (300122) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has a cash flow conversion efficiency ratio of 0.048x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.42 Billion ≈ $207.88 Million USD) by net assets (CN¥29.61 Billion ≈ $4.33 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300122 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Chongqing Zhifei Bio Products - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Chongqing Zhifei Bio Products's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Chongqing Zhifei Bio Products Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chongqing Zhifei Bio Products ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amorepacific Corp. (New)
KO:090430
|
-0.005x |
|
FLSmidth & Co.
CO:FLS
|
0.000x |
|
Bidvest Group Ltd
JSE:BVT
|
0.172x |
|
Schibsted ASA B
OL:SCHB
|
0.011x |
|
BRITISH LAND ADR/1 LS-25
F:BLDA
|
N/A |
|
Uxi Unicomp Technology Co. Ltd. A
SHG:688531
|
N/A |
|
China Vanke Co Ltd Class A
SHE:000002
|
-0.006x |
|
Keda Clean Energy Co Ltd
SHG:600499
|
0.088x |
Annual Cash Flow Conversion Efficiency for Chongqing Zhifei Bio Products (2007–2025)
The table below shows the annual cash flow conversion efficiency of Chongqing Zhifei Bio Products from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see 300122 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥16.11 Billion ≈ $2.36 Billion |
CN¥5.17 Billion ≈ $756.14 Million |
0.321x | +324.09% |
| 2024-12-31 | CN¥30.83 Billion ≈ $4.51 Billion |
CN¥-4.41 Billion ≈ $-645.91 Million |
-0.143x | -150.14% |
| 2023-12-31 | CN¥31.51 Billion ≈ $4.61 Billion |
CN¥9.00 Billion ≈ $1.32 Billion |
0.286x | +247.93% |
| 2022-12-31 | CN¥24.24 Billion ≈ $3.55 Billion |
CN¥1.99 Billion ≈ $291.06 Million |
0.082x | -82.97% |
| 2021-12-31 | CN¥17.66 Billion ≈ $2.58 Billion |
CN¥8.51 Billion ≈ $1.24 Billion |
0.482x | +13.66% |
| 2020-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
CN¥3.50 Billion ≈ $511.68 Million |
0.424x | +78.23% |
| 2019-12-31 | CN¥5.75 Billion ≈ $841.02 Million |
CN¥1.37 Billion ≈ $200.03 Million |
0.238x | +69.81% |
| 2018-12-31 | CN¥4.18 Billion ≈ $611.80 Million |
CN¥585.59 Million ≈ $85.69 Million |
0.140x | +102.07% |
| 2017-12-31 | CN¥2.94 Billion ≈ $429.85 Million |
CN¥203.61 Million ≈ $29.79 Million |
0.069x | +94.27% |
| 2016-12-31 | CN¥2.52 Billion ≈ $368.94 Million |
CN¥89.95 Million ≈ $13.16 Million |
0.036x | -60.57% |
| 2015-12-31 | CN¥2.47 Billion ≈ $361.33 Million |
CN¥223.45 Million ≈ $32.70 Million |
0.090x | +37.81% |
| 2014-12-31 | CN¥2.46 Billion ≈ $359.64 Million |
CN¥161.39 Million ≈ $23.62 Million |
0.066x | -29.19% |
| 2013-12-31 | CN¥2.39 Billion ≈ $349.62 Million |
CN¥221.58 Million ≈ $32.42 Million |
0.093x | +94.94% |
| 2012-12-31 | CN¥2.37 Billion ≈ $347.24 Million |
CN¥112.89 Million ≈ $16.52 Million |
0.048x | -51.45% |
| 2011-12-31 | CN¥2.26 Billion ≈ $330.43 Million |
CN¥221.25 Million ≈ $32.38 Million |
0.098x | +287.24% |
| 2010-12-31 | CN¥2.14 Billion ≈ $313.40 Million |
CN¥54.19 Million ≈ $7.93 Million |
0.025x | -94.57% |
| 2009-12-31 | CN¥451.69 Million ≈ $66.10 Million |
CN¥210.61 Million ≈ $30.82 Million |
0.466x | -12.05% |
| 2008-12-31 | CN¥267.06 Million ≈ $39.08 Million |
CN¥141.58 Million ≈ $20.72 Million |
0.530x | -10.72% |
| 2007-12-31 | CN¥188.03 Million ≈ $27.52 Million |
CN¥111.66 Million ≈ $16.34 Million |
0.594x | -- |
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide… Read more